Genitourinary Cancer News

SAN FRANCISCO — Moshe Ornstein, MD, spoke with Healio about a trial of intermittent therapy in patients with metastatic renal cell carcinoma presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Pembrolizumab monotherapy exhibited antitumor activity among certain patients with high-risk non-muscle-invasive bladder cancer, according to results of a single-arm phase 2 study.

SAN FRANCISCO — Atezolizumab monotherapy improved OS compared with chemotherapy among patients with PD-L1-high, cisplatin-ineligible metastatic urothelial carcinoma, according to an exploratory analysis of a randomized phase 3 study.

SAN FRANCISCO — In this video, Toni K. Choueiri, MD, gives a summary of a subgroup analysis of the KEYNOTE-564 study he presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Toni K. Choueiri, MD, highlights a biomarker analysis of CheckMate 9ER he presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Healio spoke with Toni K. Choueiri, MD, about follow-up data from the CheckMate 9ER presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Toni K. Choueiri, MD, who was the senior author, discusses an analysis of COSMIC-313 presented at ASCO Genitourinary Cancers Symposium.

A prospective phase 2 trial that evaluated risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer failed to meet a prespecified threshold of noninferiority, according to study results.

SAN FRANCISCO — In this video, Meredith M. Regan, ScD, discusses a study she presented at the annual ASCO Genitourinary Cancers Symposium that assessed treatment-free survival outcomes among patients with advanced clear cell renal cell carcinoma.

Direct oral anticoagulants showed greater efficacy and cost-effectiveness than low-molecular-weight heparin for treatment of cancer-associated thrombosis, according to data published in Annals of Internal Medicine.